NASDAQ: LONALeonabio Inc Stock
$9.03+0.01 (+0.11%)
Updated Mar 25, 2026
LONA Price
$9.03
Fair Value Price
$12.27
Market Cap
$35.61M
52 Week Low
$2.20
52 Week High
$14.21
P/E
-0.93x
P/B
1.33x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$37.72M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.12
Operating Cash Flow
-$52M
Beta
1.29
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
LONA Overview
Athira Pharma, Inc. is a late clinical-stage biopharmaceutical company developing small molecules to restore neuronal health and stop neurodegeneration brought on by Alzheimer's disease and Parkinson's disease. The company's lead candidate, ATH-1017, is in human studies for Alzheimer's disease.Known as M3 Biotechnology, Inc. until 2019/04, the company was incorporated in 2011 and is headquartered in Bothell, WA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine LONA's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
LONA
Ranked#307 of 466
Ranked#307 of 466
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $32.79 | A | |
| $16.23 | A | |
| $189.08 | A |
Be the first to know about important LONA news, forecast changes, insider trades & much more!
LONA News
Overview
Due Diligence Score
–
Industry Average (25)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how LONA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
LONA ($9.03) is undervalued by 26.41% relative to our estimate of its Fair Value price of $12.27 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
LONA ($9.03) is significantly undervalued by 26.41% relative to our estimate of its Fair Value price of $12.27 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
LONA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more LONA due diligence checks available for Premium users.
Valuation
LONA fair value
Fair Value of LONA stock based on Discounted Cash Flow (DCF)
Price
$9.03
Fair Value
$12.27
Undervalued by
26.41%
LONA ($9.03) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
LONA ($9.03) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
LONA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
LONA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.93x
Industry
25.57x
Market
31.81x
LONA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.33x
Industry
4.71x
LONA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
LONA's financial health
Profit margin
Revenue
$0.0
Net Income
-$6.6M
Profit Margin
0%
LONA's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$30.0M
Liabilities
$3.2M
Debt to equity
0.12
LONA's short-term assets ($27.03M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
LONA's short-term assets ($27.03M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
LONA's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
LONA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$4.7M
Investing
$5.7M
Financing
$0.0
LONA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
LONA vs Biotech Stocks
Leonabio Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.